Paris - Delayed Quote EUR

Valbiotis SA (ALVAL.PA)

3.9650 +0.0350 (+0.89%)
As of 2:23 PM GMT+2. Market Open.
Loading Chart for ALVAL.PA
DELL
  • Previous Close 3.9300
  • Open 3.9250
  • Bid --
  • Ask --
  • Day's Range 3.8650 - 4.0800
  • 52 Week Range 2.8200 - 7.5000
  • Volume 31,190
  • Avg. Volume 29,946
  • Market Cap (intraday) 62.556M
  • Beta (5Y Monthly) -0.30
  • PE Ratio (TTM) --
  • EPS (TTM) -0.8500
  • Earnings Date Apr 29, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 10.10

Valbiotis SA engages in the research and development of health nutrition products to prevent and control metabolic and cardiovascular diseases in France. The company develops TOTUM-63 for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II/III clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with MASLD. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.

www.valbiotis.com

48

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ALVAL.PA

Performance Overview: ALVAL.PA

Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ALVAL.PA
20.70%
CAC 40
6.45%

1-Year Return

ALVAL.PA
14.93%
CAC 40
6.02%

3-Year Return

ALVAL.PA
47.76%
CAC 40
28.32%

5-Year Return

ALVAL.PA
1.70%
CAC 40
44.01%

Compare To: ALVAL.PA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ALVAL.PA

Valuation Measures

Annual
As of 4/25/2024
  • Market Cap

    62.00M

  • Enterprise Value

    54.99M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    11.11

  • Price/Book (mrq)

    5.31

  • Enterprise Value/Revenue

    12.52

  • Enterprise Value/EBITDA

    -6.59

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -208.20%

  • Return on Assets (ttm)

    -22.94%

  • Return on Equity (ttm)

    -84.68%

  • Revenue (ttm)

    4.39M

  • Net Income Avi to Common (ttm)

    -9.14M

  • Diluted EPS (ttm)

    -0.8500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    13.74M

  • Total Debt/Equity (mrq)

    57.62%

  • Levered Free Cash Flow (ttm)

    -6.6M

Research Analysis: ALVAL.PA

Analyst Price Targets

9.20
10.10 Average
3.9650 Current
11.80 High
 

Fair Value

 

Company Insights: ALVAL.PA

People Also Watch